Medicine and Dentistry
Biological Marker
21%
Biopsy Technique
14%
Breast Cancer
76%
Breast Carcinoma
18%
Cancer Cell
15%
Cancer Staging
9%
Carcinoma
21%
Carisoprodol
9%
Cell Proliferation
11%
Colon Carcinoma
10%
Colorectal Carcinoma
21%
Cyclooxygenase 2
20%
Diseases
10%
ELAV Like Protein 1
13%
Endometriosis
18%
Endometrium
10%
Endometrium Carcinoma
21%
Epidermal Growth Factor Receptor
9%
Epidermal Growth Factor Receptor 2
16%
Estrogen Receptor
17%
Gamma Urogastrone
15%
Gene Expression
9%
Guanine Nucleotide Binding Protein
9%
Hazard Ratio
23%
Histone Deacetylase
13%
Hormone Receptor
15%
Immunohistochemistry
32%
In Situ Hybridization
12%
In Vitro
28%
Krukenberg Tumor
100%
Lymph Node
9%
Malignant Neoplasm
19%
Mammalian Target of Rapamycin
9%
Melanoma
13%
Messenger RNA
30%
Metastatic Carcinoma
16%
Neoplasm
84%
Next Generation Sequencing
10%
Ovarian Cancer
50%
Overall Survival
20%
Pathologist
11%
Primary Tumor
9%
Prognostic Factor
30%
Protein Expression
25%
Protein Kinase B
11%
Protein P53
11%
Receptor Expression
12%
Risk Stratification
10%
Tissue Microarray
10%
Uterine Cancer
30%
Keyphrases
Anthracyclines
12%
Breast Cancer
60%
Breast Cancer Patients
11%
Carcinoma
22%
Colorectal Cancer
15%
Core Needle Biopsy
17%
Cyclooxygenase-2
27%
Cyclooxygenase-2 Expression
12%
Distinct Subtypes
11%
DNA Methylation (DNAm)
14%
Endometrial Cancer
30%
Endometriosis
23%
EndoPredict
18%
Epithelial Ovarian Cancer
29%
Expression Pattern
22%
Formalin-fixed Paraffin-embedded Tissue
20%
GPER1
13%
Hazard Ratio
19%
HER2 Status
11%
High Risk
12%
Histone Deacetylase 1 (HDAC1)
12%
Hormone Receptor-positive
14%
Human Epidermal Growth Factor Receptor 2 (HER2)
30%
Human Ovarian Carcinoma
15%
Immunohistochemistry
34%
In Situ Hybridization
17%
Mammalian Target of Rapamycin (mTOR)
13%
Metastasis
13%
MRNA Expression
16%
MRNA Level
14%
Ovarian Cancer
33%
Ovarian Cancer Cells
17%
Ovarian Carcinoma
49%
Overall Survival
27%
Overexpression
25%
P53 Expression
11%
PITX2
13%
Polo-like Kinase 1 (PLK1)
18%
Poor Prognosis
10%
Prognostic Factors
25%
Prognostic Impact
30%
Programmed Death-ligand 1 (PD-L1)
18%
Protein Expression
23%
Quantitative PCR
12%
Sporadic Colorectal Cancer
13%
Tissue Microarray
10%
Triple-negative Breast Cancer
27%
Tumor
37%
Tumor Grade
14%
Tumor-infiltrating Lymphocytes
13%
